Boston Scientific (NYSE:BSX) Stock Price Target Lowered at Leerink Partners

Boston Scientific (NYSE:BSX) had its price target trimmed by Leerink Partners from $60.00 to $55.00 in a research report report published on Friday morning.

Several other research firms also recently issued reports on BSX. TD Cowen reaffirmed a “buy” rating on shares of Boston Scientific in a research note on Thursday, September 17th. UBS Group decreased their price objective on shares of Boston Scientific from $74.00 to $67.00 and set a “buy” rating for the company in a research report on Thursday, July 30th. Stifel Nicolaus set a $60.00 target price on Boston Scientific in a research note on Wednesday, July 29th. Robert W. Baird set a $56.00 target price on Boston Scientific in a research note on Thursday, July 30th. Finally, Canaccord Genuity Group dropped their target price on Boston Scientific from $70.00 to $66.00 and set a “buy” rating on the stock in a research report on Thursday, July 30th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-five have issued a Buy rating, three have issued a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, Boston Scientific presently has an average rating of “Moderate Buy” and an average price target of $68.60.

Boston Scientific Stock Up 0.9%

Shares of NYSE:BSX traded up $0.38 during mid-day trading on Friday, hitting $43.11. 1,737,588 shares of the company traded hands, compared to its average volume of 18,608,648. The firm’s 50 day simple moving average is $46.56 and its 200 day simple moving average is $50.52. The firm has a market cap of $62.47 billion, a P/E ratio of 17.43, a PEG ratio of 1.03 and a beta of 0.58. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.74 and a current ratio of 1.24. Boston Scientific has a 52-week low of $41.38 and a 52-week high of $105.65.

Boston Scientific (NYSE:BSX) last released its quarterly earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share for the quarter, topping analysts’ consensus estimates of $0.83 by $0.03. The firm had revenue of $5.44 billion during the quarter, compared to analysts’ expectations of $5.38 billion. Boston Scientific had a return on equity of 19.28% and a net margin of 17.50%. Boston Scientific’s quarterly revenue was up 7.5% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.75 EPS. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. On average, equities analysts anticipate that Boston Scientific will post 3.25 EPS for the current year.

Insider Buying and Selling at Boston Scientific

In related news, CEO Michael Mahoney acquired 186,240 shares of the firm’s stock in a transaction on Monday, August 3rd. The stock was bought at an average cost of $48.33 per share, with a total value of $9,000,979.20. Following the acquisition, the chief executive officer directly owned 1,590,024 shares in the company, valued at approximately $76,845,859.92. The trade was a 13.27% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Edward Ludwig bought 5,000 shares of the company’s stock in a transaction dated Friday, July 31st. The stock was bought at an average cost of $45.48 per share, with a total value of $227,400.00. Following the transaction, the director directly owned 30,359 shares in the company, valued at approximately $1,380,727.32. The trade was a 19.72% increase in their position. The SEC filing for this purchase provides additional information. Insiders have purchased 194,522 shares of company stock worth $9,385,210 in the last ninety days. 0.34% of the stock is owned by insiders.

Institutional Trading of Boston Scientific

Hedge funds and other institutional investors have recently bought and sold shares of the company. Kelleher Financial Advisors acquired a new position in Boston Scientific in the second quarter worth approximately $25,000. Clal Insurance Enterprises Holdings Ltd bought a new position in shares of Boston Scientific in the first quarter valued at $28,000. Rakuten Securities Inc. bought a new position in shares of Boston Scientific in the second quarter valued at $30,000. Cassaday & Co Wealth Management LLC acquired a new stake in shares of Boston Scientific during the 1st quarter valued at $32,000. Finally, Cetera Trust Company N.A acquired a new stake in shares of Boston Scientific during the 2nd quarter valued at $32,000. 89.07% of the stock is owned by institutional investors.

About Boston Scientific

Boston Scientific Corporation is a global medical technology company that develops, manufactures and markets devices used to diagnose and treat a broad range of medical conditions. Its products are designed to support minimally invasive procedures across areas including cardiovascular care, endoscopy, urology, pelvic health and neuromodulation.

The company’s portfolio includes devices for interventional cardiology and peripheral interventions, electrophysiology and cardiac rhythm management, gastrointestinal and pulmonary procedures, kidney stone and prostate treatments, urinary and pelvic health, and chronic pain management.